Trent D. Emerick, MD, MBA, FASA, has been awarded a $175,000 grant from the Beckwith Institute’s Clinical Transformation Program for his project investigating the use of psilocybin in an inpatient surgical population.
Dr. Emerick and his team, which includes Ajay D. Wasan, MD, MSc; A. Murat Kaynar, MD, MPH; Hsing-Hua Sylvia Lin, MS, PhD; and Sharvari Shivanekar, MD, will conduct a study looking at the benefits of psilocybin for inpatients with a history of surgery.
Psilocybin, a psychedelic from the tryptamine class, shows promise in regulating inflammation, inducing neural plasticity, and potentially reducing opioid consumption. Emerging research suggests that a single dose of psilocybin may provide significant and lasting relief for chronic pain and mood disorders, including depression and PTSD.